![Page 1: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/1.jpg)
Tromsø
Oslo
• Norwegian non-listed company
• Develops novel therapeutics within oncology
LTX-315 is an immunotherapy in Phase I/IIa
....improving nature´s owndefence mechanisms
![Page 2: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/2.jpg)
LTX-315 is an intratumoral cancer immunotherapy
activates the immune system and break tumor tolerance via an unique mode of action
eliminates both primary tumor and metastases
induces long-lasting protective immune response
![Page 3: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/3.jpg)
LTX-315
Induces complete regression and prevents lung metastasis in a B16 melanoma model
![Page 4: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/4.jpg)
LTX-315 has an effect on disseminated tumors
- Rapid onset of immune response -
1st 2nd
3rd
i.p.
Transformed mesenchymal sarcomas in PVG rats
Control
LTX-315
![Page 5: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/5.jpg)
Membrane-active host defense peptides
![Page 6: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/6.jpg)
Intratumoraladministration of
LTX-315
Immature DC
Antigen engulfment
Mature DC
Antigen presentation
Intradermal tumor
HMGB1
Antigens
ATP
LTX-315 induces lysis
of plasma and mitochondria membranes
Release of DAMPs from cytosol and
mitochondria
Production ofinflammatory
cytokinesfrom immune
cells
Target lesion
CTLs
Activation and augmentation of
tumor specific CTLs
Unique mechanism of action
Camilio et al. AACR 2014
Non-target lesion
![Page 7: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/7.jpg)
Rapid disruption of the cell membrane
0 min 5 min 10 min 20 minTime:
Ultra rapid membrane disruption
![Page 8: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/8.jpg)
NH
O
NH2
NH
O
NH
O
N
NH
O
NH2
NH
O
NH2
NH
O
NH
NH
O
NH2
O
NH
O
NH
NH2
NH2
NH2
OH
O
n
LTX-315De novo designed oncolytic peptide
![Page 9: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/9.jpg)
LTX-315 is an immunotherapy in Phase I/IIa
![Page 10: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/10.jpg)
A single centre study designed to evaluate safety profile and determine recommended dose
Immunological responses to the injections were exploratory endpoints
Clinical site: The Norwegian Radium Hospital
Investigator: Dr. Paal Brunsvig
No. of patients: 14 treated in three cohorts
Patient population: 9 melanomas, 4 lymphomas, 1 breast
![Page 11: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/11.jpg)
Cohort Conc.(mg/mL)
Dose
1 10 10% of tumour volume
2 20 10% of tumour volume
3 202 mg 1st injection4 mg next injections
Weekly injections of LTX-315 into one transdermallyaccessible tumour for a maximum of 6 injections
![Page 12: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/12.jpg)
Tumor-infiltrating lymphocytesBreast cancer patient – cohort 3
Haematoxilin/Eosin staining CD8+ cytotoxic T-cells
Presence of treatment-associated necrosis (left panel) and infiltration of
immune cells (TILs) (right panel)
By the courtesy of Marius Lund-Iversen, OUS
![Page 13: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/13.jpg)
Reduction of tumour volumeOccular melanoma – cohort 3
Baseline (14 x 6 mm) After 6 injections (10 x 4 mm)
By the courtesy of Olav Inge Håskjold, OUS
![Page 14: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/14.jpg)
A phase I/IIa open-label, multi-centre, multi-dose, dose escalation study of LTX-315 in patients with transdermally accessible tumours
Patients: Up to 80Duration: Approximately 2 yearsClinical sites: European investigators with clinical experience in
cancer immunotherapy
Primary endpoints
Safety profile
Tumour infiltrating lymphocytes
Secondary endpoints
Local effects
Systemic immunological response
PK profile
Anti-tumour activity
![Page 15: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/15.jpg)
Guy´s and St ThomasJames SpicerSanjeev Deva
Institut Jules BordetAhmad AwadaVakili JalalPhilippe Aftimos
UCL Saint-LucJean Francois BaurainFeby Marjuadi
DNR, OUS
Sites and Participants
Oslo
London
Brussels
![Page 16: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/16.jpg)
C12-315-03
Patient No Site
Cohort 1
001 Oslo University Hospital
002 Oslo University Hospital
003 Guy’s Hospital, London
Cohort 2
004 Jules Bordet, Brussel
005 St. Luc, Brussel
006 St. Luc, Brussel
Cohort 3 007 St. Luc, Brussel
![Page 17: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/17.jpg)
Preliminary data from cohort 1 and 2
Safety
– No issues
Efficacy
– Signs of response in injected tumors in cohort 2
![Page 18: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/18.jpg)
Dose expansion phase
Potential study groups:– Melanomas
– Sarcomas
– Head and neck
– Metastasis
Sites in EU and US
18
![Page 19: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/19.jpg)
LTX-315 is an ideal combination with checkpoint blockade inhibitors (CBIs)
![Page 20: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/20.jpg)
Preliminary data with checkpointblockade inhibitors (CBIs)
Significant synergy obtained with thecombination of LTX-315 and anti-CTLA-4 in a sarcoma mouse model
![Page 21: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/21.jpg)
LTX-315
Oncolytic peptide with a unique mode of action
Phase I/IIa clinical trial ongoing
Significant synergy with CBIs in animal models
Co-development partner
![Page 22: LTX-315 is an immunotherapy in Phase I/IIa · 2019-02-07 · LTX-315 is an immunotherapy in Phase I/IIa....improving nature´s own defence mechanisms. LTX-315 is an intratumoral cancer](https://reader033.vdocument.in/reader033/viewer/2022042910/5f3f9f6741b57214bd4a1111/html5/thumbnails/22.jpg)